Loading
A phase 3 trial of Deutenzalutamide run by Hinova Pharmaceuticals USA, Inc., terminated.
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a phase 3 interventional study registered as NCT03850795 by Hinova Pharmaceuticals USA, Inc., with 104 participants enrolled, started 2021-03-15. Conditions recorded: Prostate Cancer Metastatic and Castration-resistant Prostate Cancer. Interventions recorded: HC-1119 and Enzalutamide.
Shares Deutenzalutamide, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Deutenzalutamide, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Deutenzalutamide, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Deutenzalutamide, Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Hinova Pharmaceuticals, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/